TxCell Plans First In Man Trial Of Regulatory T-Cells
Executive Summary
Stéphane Boissel, CEO of TxCell, discusses the company's plans to advance its lead next-generation regulatory T-cell candidate into human studies, after having switched to a new platform, in a video interview with Scrip.
You may also be interested in...
Sangamo Buys TxCell To Get In Early on CAR-Tregs In Immunology
Sangamo is to pay €72m to acquire France's TxCell, a specialist in chimeric antigen receptor-modified regulatory T-cells. It hopes ultimately to apply its zinc finger nuclease gene editing technology to develop next-generation allogeneic CAR-Treg therapies for immunological conditions.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Abalos Raises €12M Series A To Develop Arenavirus-Based Cancer Therapies
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.